Innovent Biologics, Inc. announced that picankibart, a recombinant anti-interleukin 23p19 subunit antibody injection, has met all the primary endpoints and key secondary endpoints in the Phase 3 registrational study in Chinese subjects with moderate to severe plaque psoriasis.
